Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 408

1.

A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.

Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB.

Arch Gen Psychiatry. 1999 Aug;56(8):719-24.

PMID:
10435606
2.

A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.

Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E.

Alcohol Clin Exp Res. 1994 Oct;18(5):1162-7.

PMID:
7847600
3.

Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.

Karhuvaara S, Simojoki K, Virta A, Rosberg M, Löyttyniemi E, Nurminen T, Kallio A, Mäkelä R.

Alcohol Clin Exp Res. 2007 Jul;31(7):1179-87. Epub 2007 Apr 19.

PMID:
17451401
4.

Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.

Mann K, Bladström A, Torup L, Gual A, van den Brink W.

Biol Psychiatry. 2013 Apr 15;73(8):706-13. doi: 10.1016/j.biopsych.2012.10.020. Epub 2012 Dec 11.

PMID:
23237314
5.

The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.

Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SP, Oslin DW, Kampman KM, Dackis CA.

J Clin Psychopharmacol. 2006 Dec;26(6):610-25. Review.

PMID:
17110818
6.

A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.

Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B.

Alcohol Alcohol. 2000 Nov-Dec;35(6):587-93.

PMID:
11093966
7.

Naltrexone for alcohol dependence: a randomized controlled trial.

Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E.

Addiction. 2001 Nov;96(11):1565-73.

PMID:
11784454
8.

A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.

Gual A, He Y, Torup L, van den Brink W, Mann K; ESENSE 2 Study Group..

Eur Neuropsychopharmacol. 2013 Nov;23(11):1432-42. doi: 10.1016/j.euroneuro.2013.02.006. Epub 2013 Apr 3.

PMID:
23562264
9.

A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence.

Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, McCaul ME, Anthenelli R, Salloum I, Galloway G, Garbutt J, Swift R, Gastfriend D, Kallio A, Karhuvaara S.

J Clin Psychopharmacol. 2004 Aug;24(4):421-8.

PMID:
15232334
10.

Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment.

O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler HR.

J Clin Psychopharmacol. 2007 Oct;27(5):507-12.

PMID:
17873686
11.

Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.

Pettinati HM, Silverman BL, Battisti JJ, Forman R, Schweizer E, Gastfriend DR.

Alcohol Clin Exp Res. 2011 Oct;35(10):1804-11. doi: 10.1111/j.1530-0277.2011.01524.x. Epub 2011 May 16.

PMID:
21575016
12.

Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study.

Gastpar M, Bonnet U, Böning J, Mann K, Schmidt LG, Soyka M, Wetterling T, Kielstein V, Labriola D, Croop R.

J Clin Psychopharmacol. 2002 Dec;22(6):592-8.

PMID:
12454559
13.

Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial.

Heinälä P, Alho H, Kiianmaa K, Lönnqvist J, Kuoppasalmi K, Sinclair JD.

J Clin Psychopharmacol. 2001 Jun;21(3):287-92.

PMID:
11386491
14.

Nalmefene. Alcohol dependence: no advance.

[No authors listed]

Prescrire Int. 2014 Jun;23(150):150-2.

PMID:
25121147
15.

Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes.

Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, Brown RA, Gordon A, Abrams DB, Niaura RS, Asher MK.

Alcohol Clin Exp Res. 2001 Nov;25(11):1634-47.

PMID:
11707638
16.

Early treatment response in alcohol dependence with extended-release naltrexone.

Ciraulo DA, Dong Q, Silverman BL, Gastfriend DR, Pettinati HM.

J Clin Psychiatry. 2008 Feb;69(2):190-5.

PMID:
18348601
17.

Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.

Matz J, Graff C, Vainio PJ, Kallio A, Højer AM, Struijk JJ, Kanters JK, Andersen MP, Toft E.

Clin Drug Investig. 2011 Nov 1;31(11):799-811. doi: 10.2165/11592950-000000000-00000.

PMID:
21967071
18.

Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia.

Petrakis IL, O'Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH; VA Naltrexone Study Collaboration Group..

Psychopharmacology (Berl). 2004 Mar;172(3):291-7. Epub 2003 Nov 21. Erratum in: Psychopharmacology (Berl). 2004 Jul;174(2):300.

PMID:
14634716
19.

Extended naltrexone and broad spectrum treatment or motivational enhancement therapy.

Longabaugh R, Wirtz PW, Gulliver SB, Davidson D.

Psychopharmacology (Berl). 2009 Oct;206(3):367-76. doi: 10.1007/s00213-009-1615-3. Epub 2009 Jul 29.

PMID:
19639303
20.

Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial.

O'Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, Rounsaville BJ, Wu R.

Alcohol Clin Exp Res. 2007 Apr;31(4):625-34.

PMID:
17374042

Supplemental Content

Support Center